Key result
Only 6% of patients with newly diagnosed amyloidosis receive genetic testing, highlighting the need for improved access to genetics care to address health inequities in ATTRv amyloidosis.
Answers are grounded in this paper and cite their sources.
Addressing the underutilization of genetic testing through improved access to genetics care can help ameliorate health disparities in ATTRv amyloidosis.
Improved access to genetics care through eased regulations on genetic counselors and telehealth practices can ameliorate inequities in ATTRv.In the era of disease-modifying therapies for variant (hereditary) transthyretin amyloidosis (ATTRv), there are significant barriers to accurate and earlier diagnoses, when treatment is most effective.Genetic testing is a necessary, guideline-directed step in diagnosing ATTRv 1 but is vastly underutilized.A recent large real-world analysis found that only 6% of patients with newly diagnosed amyloidosis received genetic testing as part of their clinical care. 2 The most common cause of ATTRv in the U.S. is TTR Val142Ile (V142I), which is found in 3-4% of African American and 1% of Hispanic/Latino individuals with >1.5 million allele carriers in the U.S. Addressing the insufficient utilization of genetic testing for a condition that disproportionately affects minority populations can ameliorate existing health disparities.An individual's TTR status is most commonly ascertained through targeted genetic testing after presenting with signs or symptoms suspicious of amyloidosis.Many cardiologists express unease about genetic testing due to insufficient training and experience.Accordingly, the American Heart Association has advocated for genetics specialists to evaluate and counsel patients with suspected or confirmed hereditary conditions.3 This may involve a physician specialist (i.e.medical geneticist or genetic cardiologist) or genetic counselor (GC).
No takes yet. Share an insight, caveat, or question.
Liou et al. (2024) conducted an editorial in ATTRv Amyloidosis. Genetic testing and genetics care was evaluated. Only 6% of patients with newly diagnosed amyloidosis receive genetic testing, highlighting the need for improved access to genetics care to address health inequities in ATTRv amyloidosis.
Synapse has enriched 10 related papers. Consider them for comparative context: